Feb 02, 2021: “Bristol Myers Squibb announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis.
POETYK PSO-2 evaluated deucravacitinib 6 mg once daily and met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI 75), defined as at least a 75 percent improvement of baseline PASI, and a static Physician’s Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.
The trial also met multiple key secondary endpoints, including showing deucravacitinib 6 mg once daily was superior to Otezla® (apremilast) in the proportion of patients reaching PASI 75 and sPGA 0/1 at Week 16.
The overall safety profile of deucravacitinib in POETYK PSO-2 remains consistent with previously reported results and consistent with the mechanism of action of deucravacitinib.
Dr. Bruce Strober, M.D., Ph.D., Clinical Professor of dermatology at Yale University School of Medicine and Central Connecticut Dermatology, commented, “I am excited to see that the results from this second pivotal trial further support the promising efficacy and safety profile of deucravacitinib.
This represents an important step for the over 100 million people living with psoriasis worldwide, many of whom remain undertreated and are in need of new, effective oral therapies.”
POETYK PSO-2 is the second of two global Phase 3 studies demonstrating superiority of once daily deucravacitinib compared to placebo and Otezla in patients with moderate to severe plaque psoriasis.
Positive topline results from the first Phase 3 trial, POETYK PSO-1, were announced in November 2020.
The company and key investigators will complete a full evaluation of the POETYK PSO-2 data and share the detailed results at a future medical meeting.
“Deucravacitinib was designed to be a selective TYK2 inhibitor that inhibits the IL-12, IL-23 and Type 1 IFN pathways, which are implicated in multiple immune-mediated diseases.
The superior efficacy we have observed in patients with moderate to severe psoriasis, combined with the well-tolerated safety profile, are consistent with the novel mechanism of action of deucravacitinib, a potential new class of molecule,” said Samit Hirawat, M.D., executive vice president, chief medical officer, global drug development, Bristol Myers Squibb.
“The encouraging data we have seen to date suggest deucravacitinib may become an important oral treatment option for people living with psoriasis.
We look forward to discussing the results from the POETYK PSO-1 and POETYK PSO-2 registrational studies with health authorities, with the goal of offering this novel therapy to those suffering from this serious disease as soon as possible.”
Bristol Myers Squibb thanks the patients and investigators who participated in the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials.
Related News: Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 ADVANCE Study
About Deucravacitinib
Deucravacitinib is the first and only novel, once daily, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases.
Bristol Myers Squibb scientists designed deucravacitinib to be a selective TYK2 inhibitor, inhibiting interleukin (IL)-12, IL-23 and Type 1 interferon (IFN) pathways, which are implicated in the pathogenesis of psoriasis and other immune-mediated diseases.
Deucravacitinib achieves selectivity by binding to the regulatory domain of TYK2, which is structurally distinct from the Janus kinase (JAK) 1, 2 and 3 kinases.
Deucravacitinib does not inhibit JAK 1, 2, 3 at clinically relevant concentrations.
Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib.
Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.
In addition to POETYK PSO-1 and POETYK PSO-2, Bristol Myers Squibb is evaluating deucravacitinib in three other Phase 3 studies in psoriasis: POETYK PSO-3 (NCT04167462); POETYK PSO-4 (NCT03924427); POETYK PSO-LTE (NCT04036435). Deucravacitinib is not approved for any use in any country.
About the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies
PrOgram to Evaluate the efficacy and safety of deucravacitinib, a selective TYK2 inhibitor (POETYK) PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751) are global Phase 3 studies designed to evaluate the safety and efficacy of deucravacitinib compared to placebo and Otezla® (apremilast) in patients with moderate to severe plaque psoriasis.
Both POETYK PSO-1, which enrolled 666 patients, and POETYK PSO-2, which enrolled 1,020 patients, are multi-center, randomized, double-blind trials that evaluated deucravacitinib (6 mg once daily) compared with placebo and Otezla (30 mg twice daily). POETYK PSO-2 included a randomized withdrawal and retreatment period after Week 24.
The co-primary endpoints of both POETYK PSO-1 and POETYK PSO-2 were the percentage of patients who achieved Psoriasis Area and Severity Index (PASI) 75 and the percentage of patients who achieved static Physician’s Global Assessment (sPGA) score of 0 or 1 at Week 16 versus placebo.
Key secondary endpoints of the trials included the percentage of patients who achieved PASI 75 and sPGA 0/1 compared to Otezla at Week 16.”
https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Second-Pivotal-Phase-3-Psoriasis-Study-Showing-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast/default.aspx
